JW Therapeutics

OverviewSuggest Edit

JW Therapeutics is a biotech company focusing on clinical cell therapy technology. The Company is aimed to develop, transform and promote breakthrough cell-based immunotherapies to fight against cancer.


Latest Updates

Employees (est.) (Sept 2021)77(+2%)
Cybersecurity ratingAMore

Key People/Management at JW Therapeutics

Harry Lam

Harry Lam

Executive Vice President and Chief Technology Officer
Mark Gilbert

Mark Gilbert

Senior Advisor and Acting Chief Medical Officer
Xin Fu

Xin Fu

Senior Vice President and Chief Finance Officer
Alex Wu

Alex Wu

Senior Vice President and Chief Commercial Officer
James Li

James Li

Co-founder, Chairman and Chief Executive Officer
Jennifer Wang

Jennifer Wang

Executive Director, Quality
Show more

JW Therapeutics Office Locations

JW Therapeutics has an office in Suzhou Shi
Suzhou Shi, CN
Sang Tian Jie, Wuzhong Qu
Show all (4)

JW Therapeutics Financials and Metrics

Summary Metrics

Founding Date


JW Therapeutics total Funding

$90 m

JW Therapeutics latest funding size

$90 m

Time since last funding

4 years ago

JW Therapeutics investors

JW Therapeutics's latest funding round in March 2018 was reported to be $90 m. In total, JW Therapeutics has raised $90 m
Show all financial metrics

JW Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Syracuse BiopharmaJuly 26, 2020

JW Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

JW Therapeutics Online and Social Media Presence

Embed Graph

JW Therapeutics News and Updates

JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in China

The first CAR-T product independently developed in China and approved as a Category 1 biologics product, and the sixth approved CAR-T product globally Currently the only approved CAR-T product that has been simultaneously included in the National Significant New Drug Development Program,...

JW Therapeutics Announces Strategic Partnership with MediTrust Health

SHANGHAI, Aug. 20, 2021 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy, today announced that it has entered into a strategic partnership with MediTrust Health. Leveraging the...

Thermo Fisher Scientific and JW Therapeutics Announce CAR-T Partnership in China

Thermo Fisher Scientific, the world leader in serving science, has signed an agreement with JW Therapeutics, a leading cell therapy company, to ensure non-exclusive commercial access to Thermo Fisher's Gibco CTS Dynabeads CD3/CD28.

JW Therapeutics Presents Data from Pivotal Trial of Relma-cel at the 62nd ASH Annual Meeting

SHANGHAI, Dec. 7, 2020 /PRNewswire/ -- JW Therapeutics (stock code: 2126.HK), a leading clinical stage cell therapy company, presented data from the pivotal study (RELIANCE Trial) of relmacabtagene autoleucel ("relma-cel") under IND pathway at the 62nd American Society of Hematology (ASH)...

JW Therapeutics Frequently Asked Questions

  • When was JW Therapeutics founded?

    JW Therapeutics was founded in 2016.

  • Who are JW Therapeutics key executives?

    JW Therapeutics's key executives are Harry Lam, Mark Gilbert and Xin Fu.

  • How many employees does JW Therapeutics have?

    JW Therapeutics has 77 employees.

  • Who are JW Therapeutics competitors?

    Competitors of JW Therapeutics include Foghorn Therapeutics, Eutilex and SQZ Biotech.

  • Where are JW Therapeutics offices?

    JW Therapeutics has an office in Suzhou Shi.

  • How many offices does JW Therapeutics have?

    JW Therapeutics has 4 offices.